A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients

PHASE2CompletedINTERVENTIONAL
Enrollment

323

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Kidney Transplantation
Interventions
DRUG

Alefacept

Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.

DRUG

tacrolimus

The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.

DRUG

basiliximab

Administered as a 20 mg bolus injection within 2 hours prior to transplantation and a 20 mg bolus injection on Day 3.

DRUG

mycophenolate mofetil

Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.

DRUG

Corticosteroids

Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.

Trial Locations (38)

10029

Mt. Sinai School of Medicine, New York

10065

New York Presbyterian Hospital - Cornell, New York

10595

Westchester Medical Center, Valhalla

14203

Buffalo General Hospital, Buffalo

17101

Pinnacle Health at Harrisburg, Harrisburg

19104

University of Pennsylvania, Philadelphia

21201

University of Maryland Center, Baltimore

23298

Virginia Commonwealth University School of Medicine, Richmond

27599

University of North Carolina, Chapel Hill

27710

Duke University Medical Center, Durham

30921

Medical College of Georgia, Augusta, Augusta

32224

Mayo Clinic - Jacksonville, Jacksonville

32610

University of Florida, Shands Hospital, Gainesville, Gainesville

38104

Methodist University Hospital - Memphis, Memphis

40536

University of Kentucky, Lexington

44106

University Hospital of Cleveland, Cleveland

48109

University of Michigan, Ann Arbor

53792

University of Wisconsin Hospital, Madison

60612

Rush - Presbyterian - St. Lukes Medical Center, Chicago

University of Illinois at Chicago, Chicago

60637

University of Chicago Medical Center, Chicago

75246

Baylor University Medical Center, Dallas

77030

Methodist Hospital Research Institute of Houston, Houston

80045

University of Colorado Health Science Center, Aurora

84132

University of Utah Medical Center, Salt Lake City

90033

University of Southern California - University Hospital, Los Angeles

90057

St. Vincent/National Institute of Transplantation, Los Angeles

92103

UCSD, San Diego

92123

California Institute of Renal Research/Sharp Memorial Hospital, San Diego

92354

Loma Linda University Medical Center, Loma Linda

94143

University of California - San Francisco, San Francisco

95817

UC Davis Medical Center, Sacramento

97210

Legacy Transplant Services, Portland

97239

Oregon Health & Science University, Portland

98195

University of Washington Medical Center, Seattle

02111

Tufts Medical Center, Boston

02115

Brigham and Women's Hospital, Boston

07039

St. Barnabas Medical Center, Livingston

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT00543569 - A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter